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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The incidence of congenital heart disease (CHD) and severe CHD is 13.08
and 1.51/1000 live births, respectively, in Taiwan, which has had national health insurance
since 1995 and child health indices similar to those in the US. This study sought to further eluci-
date the fatality of CHD patients and their survival from a national database.
Methods: From the national health insurance database 2000e2010, we retrieved data from
CHD patients who were diagnosed at age <6 years. The survival status at discharge was ascer-
tained for estimation of survival.
Results: In total, 18,843 pediatric CHD patients were identified. The overall prevalence of CHD
was 1288 per 100 000 live-births. Severe CHD (tetralogy of Fallot (4.4%), transposition of the
great arteries (1.6%) and double outlet right ventricle (1.1%)) accounted for 11.5% of all cases.
The 1-month/5-year survival in simple and severe CHD was 99.1%/97.5% and 90.2%/76.4%,
respectively (p < 0.0001). The Kaplan-Meier survival at 5 years of age was lowest for hypo-
plastic left heart syndrome (19.7%), followed by transposition of the great arteries (66.7%),
double outlet right ventricle (69.0%), and common ventricle (66.0%). The 5-year survival of
the birth cohort in the same study period was 99.3%.of Pediatrics, National Taiwan University Hospital, No. 7 Chung-Shen South Road, Taipei 100, Taiwan,
(M.-H. Wu).
ight ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
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160 S.-J. Yeh et al.Conclusion: This national database study revealed that the survival of children with simple
CHD was still slightly lower than that of the general population and the survival of severe
CHD patients, though only accounting for one-tenth of CHD cases, remained unsatisfactory.
Such survival profiles are similar to those from Western reports and warrant a refined and dedi-
cated medical care program for children with CHD.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Recent advances in postnatal cardiac intervention have
greatly improved the outcomes of patients with congenital
heart disease (CHD)1e4; however, data regarding overall
survival rates are still scarce.3e6 The incidence of CHD
ranges from 4 to 12 per 1000 live births and is generally
estimated to be approximately 10 per 1000 live births.6e8 A
Taiwanese national population study (2000e2006) showed
that the overall incidence of CHD was 13.08 per 1000 live
births, with severe and simple CHDs occurring at rates of
1.42 and 11.66 per 1000 live births, respectively.9
The survival of individuals with simple CHD, such as
ventricular or atrial septal defects, is good and comparable
to the normal population. However, for individuals with
severe CHD, the prognoses vary considerably. Generally,
individuals with CHD requiring single ventricular palliation,
such as hypoplastic left heart syndrome (HLHS) or common
ventricle, still have poor prognoses.3,6 At the other end of
the spectrum, patients with biventricular CHD, such as
tetralogy of Fallot (ToF) or transposition of the great arteries
(TGA), survive well if properly managed. Some studies have
suggested that the long-term survival rate of ToF is approx-
imately 85e90%.10e13 The results from institutional studies
vary significantly, however, and have multiple confounding
factors. A population-based study using a registry database
may avoid institutional bias and would provide a global view
of outcomes for patients with CHD, which will be important
references for relevant healthcare policy-making.
The healthcare system in Taiwan is deemed to be sound
and the child health indices are similar to those in the USA.14
National Health Insurance (NHI) is administered by the
Bureau of National Health Insurance, Department of Health.
More than 98% of Taiwanese nationals have been obligated,
by law, to join the government-run, single-payer NHI
program since 1995.15 Using the NHI database, we investi-
gated the overall survival rates of patients with CHD and,
similarly, determined the rate for each subtype of CHD.Patients and methods
Patient identification from the National Health
Insurance database
The health care records for patients diagnosed with CHD
before the age of 6, between January 1, 2000 and
December 31, 2010, were retrieved for analysis. The
patients enrolled in this survival study were born between
2000 and 2005 and were first diagnosed with CHD before
turning 6 years old. The NHI database consists of the health
records from each medical visit, including the date of birth,sex, dates of admission or outpatient department visits,
reimbursement, and survival status upon discharge from
the hospital. Each record was encoded with a scrambled
identification number, preventing identification of the
specific individual.
CHD classifications
The CHD diagnoses were identified according to the CHD
codes of the International Classification of Diseases, Ninth
Revision, Clinical Modification. The codes encompassing
‘simple’ CHD, included 745.4 (ventricular septal defect,
VSD), 745.5 (secundum atrial septal defect, ASDII), 746.0
(anomalies of the pulmonary valve), 746.2 (Ebstein’s
anomaly), 746.3 (aortic valve stenosis, AS), 747.0 (patent
ductus arteriosus, PDA), 747.1 (coarctation of the aorta,
CoA), 747.3 (anomalies of the pulmonary artery), and
747.42 (partial anomalous pulmonary venous return). The
diagnostic codes comprising ‘severe’ CHD were 745.0
(common truncus), 745.1 (TGA), 745.11 (double outlet right
ventricle, DORV), 745.12 (congenitally corrected trans-
position of great arteries, ccTGA), 745.2 (ToF), 745.3
(common ventricle), 745.6 (endocardial cushion defect),
746.1 (tricuspid atresia and stenosis, TA), 746.5 (congenital
mitral stenosis), 746.7 (HLHS), and 747.41 (total anomalous
pulmonary venous return).9 To avoid errors caused by
incorrect tentative diagnosis and miscoding, patients were
included who had been admitted to a hospital with a major
diagnosis of CHD or who had visited the outpatient
department with a major diagnosis of CHD at least 3 times
before they reached the age of 6 years.
Statistical analyses
Data management and statistical analyses were performed
using SAS version 9.2 (SAS, Cary, NC, United States). The
patients diagnosed with a specific CHD under the age of 6
years (0e5 years old) were included to ensure adequate
CHD detection and determine the mortality rates.
The total number of deaths occurring in children under 5
years of age, and the mean and median ages at death, were
determined. The numbers of deaths were classified into the
following age groups: <1 month, 1 monthe1 year, and
those who were 1, 2, 3, and 4 years of age. The Kaplan-
Meier estimates of survival at 1-month, 1-year, and 5-years
were determined. Survival estimates and 95% confidence
intervals were computed using the Kaplan-Meier method.
The aggregate survival curves of simple, severe and all CHD
cases, in addition to the survival curves for each specific
CHD, were plotted. The log rank test was performed to
examine the differences between simple and severe CHDs,
using the two-sided method at an alpha level of 0.05.
Survival in pediatric congenital heart disease patients 161Results
The results of this study indicated that: (1) severe CHD
accounted for 11.5% of all CHD cases in Taiwan,with the three
leading diagnoses being ToF, TGA, and DORV; (2) the 5-year
survival of patients with severe CHD (76.4%) was much lower
than that of patients with simple CHD (97.5%); and (3) most of
the deaths in CHD patients occurred before 2 years of age.
A total of 18,843 patients were identified with CHD within
the first 6 years of life, and constituted the study population.
The distribution of each type of CHD is summarized in
Table 1. ASDII (31.4%) was the most common CHD, followed
by VSD (29.6%), PDA (15.4%), anomalies of the pulmonary
valve (7.1%), and ToF (4.4%). Patients with severe CHD
accounted for 11.5% of the total CHD patient population.
There were three types of severe CHD that accounted for
more than 1% of the total number of CHD cases: ToF (4.4%),
TGA (1.6%), and DORV (1.1%). The proportion of CHD cases
that required single ventricle palliation (HLHS, TA, and
common ventricle) accounted for 1.4% of CHD patients.Table 1 The distribution of congenital heart disease.
ICD-9-CM CHD type Group Number (%)
7450 Common truncus S 158 (0.7)
7451 Transposition of great arteries
(TGA)
S 351 (1.6)
74511 Double outlet right ventricle
(DORV)
S 239 (1.1)
74512 Congenitally corrected
transposition of great arteries
(ccTGA)
S 38 (0.2)
7452 Tetralogy of Fallot (ToF) S 983 (4.4)
7453 Common ventricle S 141 (0.6)
7454 Ventricular septal defect
(VSD)
E 6604 (29.6)
7455 Ostium secundum type atrial
septal defect (ASD II)
E 7021 (31.4)
7456 Endocardial cushion defect
(ECD)
S 360 (1.6)
7460 Anomalies of pulmonary valve
(aPV)
E 1575 (7.1)
7461 Tricuspid atresia or stenosis
(TA/TS)
S 74 (0.3)
7462 Ebstein’s anomaly E 79 (0.4)
7463 Aortic stenosis (AS) E 167 (0.7)
7465 Congenital mitral stenosis
(MS)
S 23 (0.1)
7467 Hypoplastic left heart
syndrome (HLHS)
S 122 (0.5)
7470 Patent ductus arteriosus
(PDA)
E 3429 (15.4)
7471 Coarctation of aorta (CoA) E 433 (1.9)
7473 Anomalies of pulmonary
artery (aPA)
E 405 (1.8)
74741 Total anomalous pulmonary
venous connection (TAPVR)
S 87 (0.4)
74742 Partial anomalous pulmonary
venous connection (PAPVR)
E 43 (0.2)
E Z simple CHD; S Z severe CHD.The event-free survivals (95% CI) of all CHD patients at 1
month, and at 1, 2, 3, 4, and 5 years ranged from 98.1%
(97.9e98.2%) at 1 month to 95.1% (94.5e95.4%) at 5 years.
Fig. 1 shows that the survival for simple CHD ranged from
99.1% at 1 month to 97.5% at 5 years; the corresponding
survival rates for severe CHD were significantly lower,
falling from 90.2% to 76.4%, respectively, (p < 0.0001, log
rank test). The 5-year survival of each specific CHD is
plotted in Fig. 2. Over the course of the study period, the
general birth population had a 5-year survival rate of 99.3%.
Table 2 shows detailed information with respect to the
age distribution of deaths and the cumulative fatality for
each CHD subtype. The major contributors to CHD-related
death were: VSD (n Z 135), ToF (n Z 119), TGA
(n Z 116), HLHS (n Z 98), and DORV (n Z 73). Most of the
deaths occurred within the first 2 years of life. For patients
with TGA, HLHS, Ebstein’s anomaly, and CoA, more than
half of the deaths occurred within the first month after
birth. The 1-month survival was lowest for HLHS (31.1%),
followed by TGA (76.6%), Ebstein’s anomaly (82.3%), and
DORV (84.9%). Patients with these four CHDs also had the
worst 1-year survival rates. Common ventricle (75.9%),
ccTGA (76.3%) and partial anomalous pulmonary venous
return (79.1%) were the other CHDs with survival rates
<80%. The 5-year survival was decreased to below 80% in
patients with congenital mitral stenosis (73.9%), partial
anomalous pulmonary venous return (76.7%), TA (78.4%),
common truncus (79.1%), and total anomalous pulmonary
venous return (79.3%). The 5-year survival was worst for
patients with HLHS (19.7%), followed by common ventricle
(66.0%), TGA (66.7%), ccTGA (68.4%), and DORV (69.0%).
Discussion
The proportion of patients with severe CHD (11.5%) was
quite close to that reported in a previous study examining
CHD in live births during the 2000e2006 period.9 With theFigure 1 Survival of all cases of CHD, and those with simple
and severe CHD. The 1-month, 1-, 2-, 3-, 4-, and 5-year survival
of all CHD patients was 98.1%, 96.1%, 95.7%, 95.3%, 95.3%,
95.1%, respectively. The 1-month, 1-, 2-, 3-, 4-, and 5-year
survival of simple CHD patients was 99.1%, 98.0%, 97.8%,
97.6%, 97.6%, 97.5%, respectively. The 1-month, 1-, 2-, 3-, 4-,
and 5-year survival of severe CHD patients was 90.2%, 81.4%,
79.4%, 77.6%, 77.4%, 76.4%, respectively.
Table 2 The age distribution of deaths in patients with congen
Disease Total number
of deaths
Age at death
(year)
(<5 y) Mean Median <
7450 Common truncus 33 0.92 0.23 1
7451 TGA 116 0.6 0.06 7
74511 DORV 73 0.92 0.2 2
74512 ccTGA 12 0.84 0.19
7452 ToF 119 1.16 0.69 2
7453 Common ventricle 48 1 0.49 1
7454 VSD 135 0.86 0.39 3
7455 ASD II 63 0.86 0.5 1
7456 ECD 70 0.85 0.4 1
7460 aPV 47 0.82 0.13 2
7461 TA/TS 16 0.91 0.38
7462 Ebstein’s anomaly 18 0.22 0.04 1
7463 AS 16 1.3 0.56
7465 MS 6 0.94 0.56
7467 HLHS 98 0.13 0.04 7
7470 PDA 66 0.61 0.32 1
7471 CoA 69 0.42 0.05 4
7473 aPA 68 0.81 0.1 3
74741 TAPVR 18 0.5 0.19
74742 PAPVR 10 0.71 0.31
Figure 2 Survival of specific CHD, stratified by the Interna-
tional Classification of Diseases, Ninth Revision codes.
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NHI database, the 5-year survival of CHD children in Taiwan
during the decade spanning 2000e2010 was 97.5% and
76.4% for simple and severe CHD, respectively. The survival
of patients with simple CHD was slightly lower than that of
the general population (99.3%), but the survival rate of
patients with severe CHD was far from satisfactory. Such
medical challenges have also recently been reported in
Belgium and England,2,6 where the mortality rates for CHD
patients were similar to those reported in Taiwan.2,6
Nevertheless, a trend of improved outcome was still
evident; the mortality rate declined when compared to
that reported in the 1980s and 1990s.16e18
As shown in Table 2, the median age of death is consis-
tently less than the mean age. The highest proportion of
CHD-related deaths, particularly for severe CHD patients,
was observed within the first 2 years after birth. Early
fatalities have also been observed in other studies.3,6 Most
patients with TGA, HLHS, anomalies of the pulmonary
artery, anomalies of the pulmonary valve, and CoA died
within the first month, reflecting the natural history of the
disease and intervention-related complications. For simple
lesions, such as ASDII and VSD, CHD-related deaths may
occur later, in adulthood.3
As shown in the present study, the major contributors
towards CHD-related deaths included VSD, ToF, TGA, HLHS,
and DORV. In the United States, HLHS was the largest
contributor to CHD deaths before the age of 6, followed by
ToF, TGA, pulmonary atresia, and PDA.3 VSD is the CHD
most commonly associated with chromosome anomalies or
syndromic combinations, and patients with these disorders
were not excluded form the current analyses. The VSD-
related deaths might therefore be overrepresented withinital heart disease below the age of 5 years.
Number of deaths Kaplan-Meier
estimate of survival
(%)
1 mo 1 moe1 y 1 2 3 4 <1 mo <1 y <5 y
4 14 0 4 0 1 99.9 82.3 79.1
0 28 7 7 1 3 76.6 71.8 66.7
9 28 6 3 1 6 84.9 74.9 69.0
5 3 2 1 0 1 86.8 76.3 68.4
6 48 20 14 3 8 96.3 92.2 87.8
2 22 4 8 0 2 89.4 75.9 66.0
9 66 12 9 2 7 99.3 98.4 97.9
2 33 9 5 3 1 99.8 99.3 99.1
8 35 9 4 1 3 94.4 85.3 80.6
1 15 7 2 2 2 98.3 97.7 97.0
6 5 2 2 0 1 91.9 85.1 78.4
2 5 1 0 0 0 82.3 78.5 77.2
4 8 2 1 1 0 96.4 92.2 90.4
1 2 1 0 0 0 95.6 82.6 73.9
2 25 0 0 1 0 31.1 20.5 19.7
7 37 9 2 1 0 99.4 98.4 98.1
2 20 3 3 0 1 88.9 85.7 83.8
4 18 5 6 0 5 89.9 86.7 83.2
1 15 1 0 0 1 92.0 81.6 79.3
1 8 0 0 0 1 97.7 79.1 76.7
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rates of ToF patients in the present study were 92.5%,
90.7%, and 87.8%, respectively, which is better than the
results reported from Belgium (83%, 83%, and approxi-
mately 80%, respectively).6 Since the incidence of ToF is
generally higher in Western countries,6 the relatively high
number of deaths from ToF in the current study may be
related, at least in part, to the high number of newborns
with ToF in Taiwan. The current study also reported much
worse survival rates of HLHS (20.5% and 19.7% at 1 and
5 years, respectively) than that reported in the Belgian
study.6 Since the incidence of HLHS in Taiwan is only
approximately one-fourth of that observed in Western
countries, difficulties in learning how to treat this CHD may
explain the poor outcomes.8,9
For patients with ToF and TGA, differences were noted
between the institutional reports and the present study. In
this national database study, the 5-year survival was 87.8%
and 66.7% for ToF and TGA patients, respectively. These
estimates are lower than those of the institutional reports,
which have estimated the long-term survival rate for ToF to
be 90.5% and for the 2-year survival rate TGA patients to be
89%.11,19 Further studies to determine the determinants of
outcomes may be required.
Study limitations
Despite using the NHI nationwide database, some CHD
patients without NHI coverage could not be assessed in this
study. Moreover, some CHD patients may die before
admission due to sudden collapse or by being refractory to
resuscitation. These patients are included in our study,
leading to a potential overestimation of the survival of
pediatric CHD patients. As the NHI coverage in Taiwan was
more than 98% and medical resources are easily accessible,
we believe that the influence of the abovementioned
limitations on our results should be minimal. However, we
were unable to access the National Death Registry due to
the law concerning the protection of privacy. Furthermore,
we could not validate the specific details of the CHD by
chart review to re-confirm the diagnosis and the exact
cause of death, which is another limitation of our nation-
wide database study.
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